Towards a healthier discount procedure.

Area of Science:

• Health Economics
• Decision Analysis
• Pharmacoeconomics

Background:

• Current pharmacoeconomic guidelines typically mandate uniform discounting for both monetary costs and health outcomes.
• This standard practice is largely based on theoretical arguments like the Weinstein and Stason consistency argument and the Keeler and Cretin paralyzing paradox.
• Recent scholarly discourse questions the necessity and theoretical underpinnings of applying identical discount rates.

Purpose of the Study:

• To critically evaluate the adequacy of current pharmacoeconomic discounting practices.
• To explore alternative theoretical frameworks for determining appropriate discount rates for health outcomes.
• To investigate the implications of differing discount rates for money and health in economic evaluations.

Main Methods:

• Review of existing theoretical arguments and national guidelines for pharmacoeconomic research.
• Analysis of recent scholarly contributions proposing alternative discounting methodologies.
• Examination of economic principles related to the valuation of future health gains.

Main Results:

• The theoretical basis for using identical discount rates for money and health is increasingly considered weak.
• Alternative approaches suggest health discount rates should be informed by factors such as expected life expectancy growth and diminishing marginal utility of health.
• Authors like Van Hout, Gravelle, and Smith propose that the value of health may grow over time, necessitating downward adjustments to discount rates applied to health effects.

Conclusions:

• The uniform discounting of money and health in pharmacoeconomics warrants re-evaluation.
• A differentiated approach to discounting, particularly for health outcomes, is theoretically justifiable and practically relevant.
• Future pharmacoeconomic research should consider novel frameworks for discount rate determination that account for the unique characteristics of health.